CinCor Pharma, Inc. (CINC)

NASDAQ: CINC · IEX Real-Time Price · USD
26.53
+0.90 (3.51%)
Nov 25, 2022 1:00 PM EDT - Market closed
3.51%
Market Cap 1.12B
Revenue (ttm) n/a
Net Income (ttm) -88.09M
Shares Out 40.81M
EPS (ttm) -6.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 111,125
Open 25.5
Previous Close 25.63
Day's Range 25.26 - 26.69
52-Week Range 13 - 43.15
Beta n/a
Analysts Buy
Price Target 63.58 (+139.7%)
Earnings Date Nov 14, 2022

About CINC

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. [Read more]

Industry Biotechnology
IPO Date Jan 7, 2022
CEO Marc de Garidel
Employees 19
Stock Exchange NASDAQ
Ticker Symbol CINC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CINC stock is "Buy." The 12-month stock price forecast is 63.58, which is an increase of 139.65% from the latest price.

Price Target
$63.58
(139.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:

3 days ago - GlobeNewsWire

CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place o...

2 weeks ago - GlobeNewsWire

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hyper...

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol

2 weeks ago - GlobeNewsWire

CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldos...

Clinically significant and dose-dependent reduction in blood pressure with baxdrostat

2 weeks ago - GlobeNewsWire

CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective Nov...

2 weeks ago - GlobeNewsWire

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, t...

3 weeks ago - GlobeNewsWire

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

Positive topline Phase 2 BrigHtn data demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension

3 weeks ago - GlobeNewsWire

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Neph...

WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as par...

1 month ago - GlobeNewsWire

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small m...

1 month ago - GlobeNewsWire

3 Soaring Biotech Stocks That Could Climb Much Higher

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

Other symbols: BLTEPLRX
1 month ago - The Motley Fool

CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat at the Upcoming 29th International Society o...

WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as par...

1 month ago - GlobeNewsWire

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hype...

WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients ...

1 month ago - GlobeNewsWire

CinCor Pharma to Participate at Upcoming September Investor Conferences

WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual Bi...

2 months ago - GlobeNewsWire

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Card...

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster ...

3 months ago - GlobeNewsWire

Insiders Buy Around $70M Of 4 Stocks: Six Flags Entertainment, MGM Resorts And More

Although US stocks closed higher on Monday, there were a few notable insider trades.

Other symbols: MGMSIXECL
3 months ago - Benzinga

CinCor Pharma Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat,...

3 months ago - GlobeNewsWire

CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat,...

3 months ago - GlobeNewsWire

CinCor Pharma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat,...

3 months ago - GlobeNewsWire

CinCor Reports Second Quarter Financial Results and Provides Corporate Update

Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension

3 months ago - GlobeNewsWire

CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldoster...

Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 ...

3 months ago - GlobeNewsWire

CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for...

Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks

4 months ago - GlobeNewsWire

7 No-Brainer Biotech Stocks to Add to Your Buy List

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on...

Other symbols: BIIBCRSPEBSHRMYVIGL
5 months ago - InvestorPlace

CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study

CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and ...

5 months ago - Benzinga

CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor...

figHTN-CKD is CinCor's fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107)

5 months ago - GlobeNewsWire

CinCor Pharma to Present at the Jefferies Healthcare Conference

WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New Yo...

5 months ago - GlobeNewsWire